April 24, 2025 08:00 iCoat Medical raises SEK 8.5 Million in bridge financing ahead of upcoming Phase 2b kidney transplantation study Read more
August 26, 2024 15:45 iCoat Medical to make an oral abstract presentation at ASN Kidney Week 2024 Read more
August 19, 2024 08:00 iCoat Medical’s co-founder and Head of Chemistry Prof. Yuji Teramura wins the Award of Japanese Society for Biomaterials Read more
June 25, 2024 08:00 iCoat Medical receives positive feedback from EMA around planned clinical study EMPIRe and completed preclinical program Read more
June 13, 2024 11:45 iCoat Medical successfully completed long-term follow-up part of its clinical study ATMIRe Read more
June 10, 2024 13:00 iCoat Medical’s preclinical results presented at the prestigious World Biomaterials Congress in South Korea Read more
April 24, 2024 17:00 Communiqué from iCoat Medical AB’S (PUBL) ANNUAL GENERAL MEETING 24 april 2024 Read more
March 19, 2024 16:00 iCoat Medical’s CMO Dr. Alireza Biglarnia wins grant for transplant research Read more
February 21, 2024 16:00 iCoat Medical forms a Scientific Advisory Board to strengthen its transplant expertise Read more
February 19, 2024 16:00 iCoat Medical’s upcoming Phase 2b study EMPIRe with iCM012 fundamental to updated clinical development plan Read more
November 20, 2023 16:00 Swedish MPA looks favorably on iCoat Medical’s continued and expanded development of iCM012 Read more
September 19, 2023 08:00 iCoat Medical announces positive results from Phase 1/2a trial ATMIRe in kidney transplantation Read more
May 10, 2023 17:35 iCoat Medical completes enrollment in First In Human study of TUM012 in kidney transplantation Read more
April 20, 2023 16:30 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 20 APRIL 2023 Read more
December 17, 2022 10:28 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) EXTRAORDINARY GENERAL MEETING 16 DECEMBER 2022 Read more
October 19, 2022 17:00 The U.S. Food and Drug Administration has granted iCoat Medical Orphan Drug Designation for TUM012 in the United States Read more
October 11, 2022 13:00 ICOAT MEDICAL ANNOUNCES SECOND INTERIMDATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Read more
August 10, 2022 ICOAT MEDICAL ANNOUNCES INTERIM DATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Read more
June 16, 2022 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 15 JUNE 2022 Read more
June 13, 2022 iCoat Medical to present at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022 Read more
June 4, 2022 iCoat Medical to present at the 29th International Congress of The Transplantation Society in Buenos Aires, Argentina in September 2022 Read more
April 25, 2022 iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden Read more
April 21, 2022 The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU Read more
January 11, 2022 Mattias Springare joins iCoat Medical as CFO and Head of Investor Relations Read more
December 22, 2021 iCoat Medical receives approval from the Swedish MPA and starts its First in Human trial at Skåne University Hospital Read more
December 21, 2021 Communiqué from iCoat Medical’s (PUBL) extraordinary general meeting 15 December 2021 Read more
November 26, 2021 The European Union Intellectual Property Office grants iCoat Medical funding for IP assessment Read more
November 15, 2021 Carl Bjartmar is proposed as a new member to iCoat Medical’s Board of Directors Read more
July 24, 2021 iCoat Medical has successfully raised 40 MSEK in a Pre-IPO to fund its upcoming First In Human-trial Read more